Pfizer’s Abboject comes out of patent infringement case with flying colors

A Pfizer unit has recently backed a win against the claims made by Belcher Pharmaceuticals that its adrenaline shot named ‘Abboject’ infringed one of the Belcher adrenaline patents. The same was upheld by the U.S. Court of Appeals for the Federal Circuit.

U.S. Circuit Judge Jimmie Reyna wrote for a unanimous three-judge panel: “Belcher’s patent was declared invalid because of the fact that the company purposely omitted some important information from its application. This mere fact would have kept the U.S. Patent and Trademark Office from awarding the patent. Belcher’s chief science officer Darren Rubin represented to the PTO that its formulation was a novel invention that was contrary to the prior art and solved problems that seemed impossible, while also telling the U.S. Food and Drug Administration about earlier formulations with similar specifications.”

Largo (Florida-based) Belcher applied for U.S. Food and Drug Administration (FDA) approval for an injectable formulation of adrenaline in the year 2012. Later, it applied for a patent dealing with the drug in the year 2014. This patent was then issued in the year 2016. The drug is claimed of having several potential usages including countering allergic reactions, treating cardiac arrest, and providing relief for asthma and COPD. Belcher sued Lake Forest in the year 2017. Lake Forest is Illinois based Hospira. Belcher alleged in its application for U.S. Food and Drug Administration approval that Abboject deliberately infringed its patent.

In that case, U.S. District Judge Leonard Stark in Delaware ruled last year: “The patent is invalid based on inequitable conduct, finding Rubin withheld three pieces of information that would have prevented the U.S. Patent and Trademark Office from awarding the patent.” The case can be reached with the name of “Belcher Pharmaceuticals LLC v. Hospira Inc, U.S. Court of Appeals for the Federal Circuit” bearing case no. 20-1799.